Crinetics Pharmaceuticals...

AI Score

0

Unlock

38.45
-0.85 (-2.16%)
At close: Feb 06, 2025, 2:41 PM
undefined%
Bid 38.45
Market Cap 3.57B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -3.7
PE Ratio (ttm) -10.39
Forward PE n/a
Analyst Buy
Ask 38.56
Volume 335,862
Avg. Volume (20D) 850,738
Open 39.17
Previous Close 39.30
Day's Range 38.44 - 39.72
52-Week Range 35.51 - 62.53
Beta undefined

About CRNX

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat c...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 18, 2018
Employees 290
Stock Exchange NASDAQ
Ticker Symbol CRNX

Analyst Forecast

According to 12 analyst ratings, the average rating for CRNX stock is "Buy." The 12-month stock price forecast is $73, which is an increase of 89.86% from the latest price.

Buy 91.67%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Crinetics Pharmaceuticals Inc. is scheduled to release its earnings on Feb 26, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+1.26%
Crinetics Pharmaceuticals shares are trading highe... Unlock content with Pro Subscription
6 months ago
-6.11%
Crinetics Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results. Additionally, the company announced its CFO will be departing and Oppenheimer lowered its price target on the stock from $74 to $73.